Bazarbashi S, Abdelmotal AS, Arabi T, Fallatah W, et al. Docetaxel versus androgen receptor pathway inhibitors as first-line therapy for metastatic castration-resistant prostate cancer after doublet therapy: a multicenter retrospective study from Saudi Arabia. BMC Urol 2025;25:306.
PMID: 41430171